Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: Cancer Res. 2016 Oct 20;76(24):7118–7129. doi: 10.1158/0008-5472.CAN-16-0298

Table 1.

Clinicopathologic characteristics of SPCRP analyzed in this study.

1 2 3 4 5 6 7 8 9 10 11 12 13
Clinical findings
Age, y 68 62 63 79 64 51 64 58 66 65 70 65 65
Laterality L L L R R R L R R L L L L
Size, cm 0.9 0.8 1.2 U 1.8 0.8 1.4 0.6 0.9 1.5 1.3 1.2 0.9
LN metastasis/ sampled U 0/2 NP U 0/2 0/3 0/1 U 0/3 0/2 0/2 0/4 U
Outcome/mo U NED/77 U U NED/31 NED/30 NED/29 U NED/20 NED/37 NED/12 U U
Treatment U S/XRT U U U S S/XRT U S/C S/XRT/C U U U
Cancer history U + U U - + - U - - - U U
Immunohistochemical features
CK5/6 + + + + + + Rare + - + + Focal + Focal + +
CK7 + + + + + + + + + - + + NP
CK 34βE12 NP + + + + + - + + + + + NP
CK AE1/AE3 NP + NP + + NP + + + + + + NP
p63 - - - - - - - - - - - - -
SMMHC - - - - - - - - - - - NP -
Calponin - - - - - - - - - NP - - NP
ER - - <10% + - - <10% + <10% + - - <10% + <10% + - -
PR - - <10% + - - <10% + - - - - - - -
HER2 NP - NP NP - - - - - - - - -
AR NP - - - - - - - - NP - - Focal +
GCDFP-15 Focal + - Focal + Focal + Focal + Focal + - - Focal + - Focal + - Focal +
Mammaglobin Focal + + Focal + Focal + Focal + - - - - - Focal + + NP
TTF-1 - - NP - - - - - - - - - -
Thyroglobulin NP - NP - - NP - - - - - - -

Abbreviations: AR, androgen receptor; C, chemotherapy (carboplatin and taxol); CK, cytokeratin; ER, estrogen receptor; GCDFP-15; gross cystic disease fluid protein-15; L, left; LN, lymph node; mo, months; NED, no evidence of disease; NP, not performed; R, right; SMMHC, smooth muscle myosin heavy chain; TTF-1, thyroid transcription factor-1; U, unknown; XRT, radiation; y, years

HHS Vulnerability Disclosure